Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M

• Published in: Respiratory research Vol. 16; no. 1; p. 14
• Main Authors: Kwofie, Karen, Scott, Matthew, Rodrigues, Rebecca, Guerette, Jessica, Radford, Katherine, Nair, Parameswaran, Richards, Carl D
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.02.2015; BioMed Central
• Subjects: Analysis; Asthma; Cells, Cultured; Chemokine CCL2 - metabolism; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Gene Expression Regulation; Humans; Interleukin-17 - immunology; Interleukin-17 - metabolism; Interleukin-17 - pharmacology; Interleukin-6 - metabolism; Myocytes, Smooth Muscle - drug effects; Myocytes, Smooth Muscle - immunology; Myocytes, Smooth Muscle - metabolism; Oncostatin M - immunology; Oncostatin M - metabolism; Oncostatin M - pharmacology; p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors; p38 Mitogen-Activated Protein Kinases - metabolism; Phosphorylation; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins c-akt - antagonists & inhibitors; Proto-Oncogene Proteins c-akt - metabolism; Respiratory System - drug effects; Respiratory System - immunology; Respiratory System - metabolism; RNA, Messenger - metabolism; Signal Transduction - drug effects; STAT3 Transcription Factor - antagonists & inhibitors; STAT3 Transcription Factor - metabolism; Canada
• ISSN: 1465-993X; 1465-9921; 1465-993X
• DOI: 10.1186/s12931-014-0164-4

Regulation of human airway smooth muscle cells (HASMC) by cytokines contributes to chemotactic factor levels and thus to inflammatory cell accumulation in lung diseases. Cytokines such as the gp130 family member Oncostatin M (OSM) can act synergistically with Th2 cytokines (IL-4 and IL-13) to modulate lung cells, however whether IL-17A responses by HASMC can be altered is not known. To determine the effects of recombinant OSM, or other gp130 cytokines (LIF, IL-31, and IL-6) in regulating HASMC responses to IL-17A, assessing MCP-1/CCL2 and IL-6 expression and cell signaling pathways. Cell responses of primary HASMC cultures were measured by the assessment of protein levels in supernatants (ELISA) and mRNA levels (qRT-PCR) in cell extracts. Activation of STAT, MAPK (p38) and Akt pathways were measured by immunoblot. Pharmacological agents were used to assess the effects of inhibition of these pathways. OSM but not LIF, IL-31 or IL-6 could induce detectable responses in HASMC, elevating MCP-1/CCL2, IL-6 levels and activation of STAT-1, 3, 5, p38 and Akt cell signaling pathways. OSM induced synergistic action with IL-17A enhancing MCP-1/CCL-2 and IL-6 mRNA and protein expression, but not eotaxin-1 expression, while OSM in combination with IL-4 or IL-13 synergistically induced eotaxin-1 and MCP-1/CCL2. OSM elevated steady state mRNA levels of IL-4Rα, OSMRβ and gp130, but not IL-17RA or IL-17RC. Pharmacologic inhibition of STAT3 activation using Stattic down-regulated OSM, OSM/IL-4 or OSM/IL-13, and OSM/IL-17A synergistic responses of MCP-1/CCL-2 induction, whereas, inhibitors of Akt and p38 MAPK resulted in less reduction in MCP-1/CCL2 levels. IL-6 expression was more sensitive to inhibition of p38 (using SB203580) and was affected by Stattic in response to IL-17A/OSM stimulation. Oncostatin M can regulate HASMC responses alone or in synergy with IL-17A. OSM/IL-17A combinations enhance MCP-1/CCL2 and IL-6 but not eotaxin-1. Thus, OSM through STAT3 activation of HASMC may participate in inflammatory cell recruitment in inflammatory airway disease.